Metabolic dysfunction-associated steatotic liver disease throughout the liver transplant cycle: a comprehensive review

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in global prevalence and becoming a leading indication for liver transplantation (LT). The management of MASLD has been well-studied in the pre-LT setting, and we are entering into a golden era of pharmacologic options designed to resolve steatohepatitis and reverse fibrosis. However, the implications of MASLD on organ allocation, risk of post-LT recurrence, and optimal post-LT management remain topics of ongoing investigation. One such unique challenge is the growing necessity to use steatotic organs to address the shortage of available organs for all waitlisted patients, while ensuring acceptable outcomes through careful case selection. Additionally, how best to screen, diagnose, and manage post-LT graft steatosis remains an ongoing topic of debate, given the high rates of recurrence or de novo occurrence in patients transplanted for non-MASLD-related etiologies of liver disease. This comprehensive review explores the impact of MASLD across the disease continuum, given it is a chronic illness with a complex pathophysiology and is influenced by other comorbidities and certain medications.

Keywords

MASLD / MASH / liver transplant / graft steatosis

References

[1] Younossi ZM,Paik JM,Van Dongen C.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023;77:1335-47 PMCID:PMC10026948

[2] Ludwig J,McGill DB.Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.Mayo Clin Proc1980;55:434-8

[3] Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86. PMCID:PMC10653297

[4] Rinella ME.From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease.J Lipid Res2024;65:100485 PMCID:PMC10824973

[5] Cholankeril G,Hu M.Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes.Dig Dis Sci2017;62:2915-22

[6] Younossi ZM,Al Shabeeb R.The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease.Hepatol Commun2024;8:e0352 PMCID:PMC10749707

[7] Taylor RS,Bayliss S.Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.Gastroenterology2020;158:1611-25.e12

[8] Dulai PS,Patel J.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.Hepatology2017;65:1557-65 PMCID:PMC5397356

[9] Newsome PN,Deeks JJ.FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.Lancet Gastroenterol Hepatol2020;5:362-73 PMCID:PMC7066580

[10] Singh S,Wang Z,Murad MH.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol2015;13:643-54.e1-9 PMCID:PMC4208976

[11] Simon TG,Hagström H,Ludvigsson JF.Progression of non-alcoholic fatty liver disease and long-term outcomes: a nationwide paired liver biopsy cohort study.J Hepatol2023;79:1366-73 PMCID:PMC11146347

[12] Sanyal AJ,Ratziu V.The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials.Hepatology2019;70:1913-27

[13] Schattenberg JM,Reinhart B.Identification of fast progressors among patients with nonalcoholic steatohepatitis using machine learning.Gastro Hep Adv2024;3:101-8 PMCID:PMC11307632

[14] Vilar-Gomez E,Calzadilla-Bertot L.Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.Gastroenterology2015;149:367-78.e5

[15] Patel NS,Peterson MR.Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2015;13:561-8.e1 PMCID:PMC4333065

[16] Patel NS,Gonzalez M.Weight loss decreases magnetic resonance elastography estimated liver stiffness in nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2017;15:463-4 PMCID:PMC5476292

[17] Koutoukidis DA,Tomlinson JW,Aveyard P.Association of weight changes with changes in histological features and blood markers in nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2022;20:e538-47

[18] Malespin MH,Watkins SE.Weight loss and weight regain in usual clinical practice: results from the TARGET-NASH observational cohort.Clin Gastroenterol Hepatol2022;20:2393-5.e4

[19] Keating SE,George J.Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis.J Hepatol2012;57:157-66

[20] Thoma C,Trenell MI.Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.J Hepatol2012;56:255-66

[21] Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB; NASH CRN Research Group. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106:460-8. PMCID:PMC3070294

[22] Hashida R,Bekki M.Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review.J Hepatol2017;66:142-52

[23] Vitaglione P,Mazzone G.Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins.Hepatology2010;52:1652-61

[24] Wijarnpreecha K,Ungprasert P.Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis.Eur J Gastroenterol Hepatol2017;29:e8-12

[25] Liu F,Wu G.Coffee consumption decreases risks for hepatic fibrosis and cirrhosis: a meta-analysis.PLoS One2015;10:e0142457 PMCID:PMC4640566

[26] Kennedy OJ,Buchanan R,Hayes PC.Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis.Aliment Pharmacol Ther2016;43:562-74

[27] Bravi F,Bosetti C,La Vecchia C.Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies.Eur J Cancer Prev2017;26:368-77

[28] Chen YP,Hu YB,Zheng MH.A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease.Clin Nutr2019;38:2552-7

[29] Zhang S,Zhang Q.Association between nut consumption and non-alcoholic fatty liver disease in adults.Liver Int2019;39:1732-41

[30] Chen BB,Pan X.Association between nut intake and non-alcoholic fatty liver disease risk: a retrospective case-control study in a sample of Chinese Han adults.BMJ Open2019;9:e028961 PMCID:PMC6731785

[31] Semmler G,Wernly S.Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease.PLoS One2020;15:e0244514 PMCID:PMC7774938

[32] Zelber-Sagi S,Fliss Isakov N.High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance.J Hepatol2018;68:1239-46

[33] Abdelmalek MF, Suzuki A, Guy C, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961-71. PMCID:PMC2922495

[34] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. 2024;17:374-444. PMCID:PMC11299976

[35] Eslam M,Wong VW.The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.Hepatol Int2020;14:889-919

[36] Semmler G,Reiberger T.Diet and exercise in NAFLD/NASH: beyond the obvious.Liver Int2021;41:2249-68 PMCID:PMC9292198

[37] Darmon N.Contribution of food prices and diet cost to socioeconomic disparities in diet quality and health: a systematic review and analysis.Nutr Rev2015;73:643-60 PMCID:PMC4586446

[38] Moriya A,Ohguchi S.Roles of alcohol consumption in fatty liver: a longitudinal study.J Hepatol2015;62:921-7

[39] Dunn W,Brunt EM.Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).J Hepatol2012;57:384-91 PMCID:PMC3399018

[40] Hashimoto Y,Kojima T.Modest alcohol consumption reduces the incidence of fatty liver in men: a population-based large-scale cohort study.J Gastroenterol Hepatol2015;30:546-52

[41] Kwon I,Moon JH.Effects of moderate alcohol drinking in patients with nonalcoholic fatty liver disease.Gut Liver2019;13:308-14 PMCID:PMC6529167

[42] Kwon HK,Conjeevaram HS.Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease.Liver Int2014;34:129-35

[43] Chang Y,Kim Y.Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study.Hepatology2019;69:64-75

[44] Long MT,Hoffmann U,Naimi TS.Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2020;18:1831-41.e5 PMCID:PMC7569606

[45] Åberg F,Salomaa V.Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts.Hepatology2020;71:835-48

[46] Marti-Aguado D,Vilar-Gomez E.Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.J Hepatol2024;81:930-40

[47] Plauth M,Dasarathy S.ESPEN guideline on clinical nutrition in liver disease.Clin Nutr2019;38:485-521 PMCID:PMC6686849

[48] Rinella ME,Siddiqui MS.AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.Hepatology2023;77:1797-835 PMCID:PMC10735173

[49] Sanyal AJ, Chalasani N, Kowdley KV, et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85. PMCID:PMC2928471

[50] Vilar-Gomez E,Gawrieh S.Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis.Hepatology2020;71:495-509

[51] Klein EA,Tangen CM.Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).JAMA2011;306:1549-56 PMCID:PMC4169010

[52] Schürks M,Rist PM,Kurth T.Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials.BMJ2010;341:c5702 PMCID:PMC2974412

[53] Bjelakovic G,Gluud LL,Gluud C.Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.JAMA2007;297:842-57

[54] Vilar-Gomez E,Wong VW.Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic steatohepatitis-related, child-pugh a cirrhosis.Clin Gastroenterol Hepatol2021;19:136-45.e6

[55] Zhou J,Lei X.Meta-analysis: the efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.Ann Hepatol2020;19:320-8

[56] Belfort R,Brown K.A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.N Engl J Med2006;355:2297-307

[57] Aithal GP,Kaye PV.Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.Gastroenterology2008;135:1176-84

[58] Majzoub AM,Barnard A.Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.Aliment Pharmacol Ther2021;54:880-9 PMCID:PMC8711247

[59] Armstrong MJ, Gaunt P, Aithal GP, et al; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679-90.

[60] Capehorn MS,Furberg JK.Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).Diabetes Metab2020;46:100-9

[61] O'Neil PM,McGowan B.Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.Lancet2018;392:637-49

[62] Newsome PN, Buchholtz K, Cusi K, et al; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113-24.

[63] Flint A,Hockings P.Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.Aliment Pharmacol Ther2021;54:1150-61 PMCID:PMC9292692

[64] Newsome PN,Engebretsen KA.Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial.Aliment Pharmacol Ther2024;60:1525-33 PMCID:PMC11599791

[65] Loomba R, Hartman ML, Lawitz EJ, et al; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299-310.

[66] Loomba R, Abdelmalek MF, Armstrong MJ, et al; NN9931-4492 investigators. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511-22. PMCID:PMC10792518

[67] Peverelle M,Peverelle J,Testro A.Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis.World J Gastroenterol2023;29:6165-7 PMCID:PMC10768411

[68] Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.

[69] Harrison SA,Dubourg J,Noureddin M.Clinical trial landscape in NASH.Clin Gastroenterol Hepatol2023;21:2001-14

[70] Institute for Clinical and Economic Review. Non-Alcoholic Steatohepatitis. An assessment of resmetirom and obeticholic acid for NASH. Available from: https://icer.org/assessment/non-alcoholic-steatohepatitis-2023/. [Last accessed on 23 Dec 2024].

[71] Mingrone G,De Gaetano A.Bariatric surgery versus conventional medical therapy for type 2 diabetes.N Engl J Med2012;366:1577-85

[72] Mingrone G,De Gaetano A.Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.Lancet2015;386:964-73

[73] Mingrone G,De Gaetano A.Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.Lancet2021;397:293-304

[74] Schauer PR,Wolski K.Bariatric surgery versus intensive medical therapy in obese patients with diabetes.N Engl J Med2012;366:1567-76 PMCID:PMC3372918

[75] Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med. 2014;370:2002-13. PMCID:PMC5451259

[76] Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376:641-51. PMCID:PMC5451258

[77] Ikramuddin S,Lee WJ.Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the diabetes surgery study randomized clinical trial.JAMA2013;309:2240-9 PMCID:PMC3954742

[78] Ikramuddin S,Lee WJ.Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the diabetes surgery study.JAMA2018;319:266-78 PMCID:PMC5833547

[79] Lim WH,Ng CH.Foregut bypass vs. restrictive bariatric procedures for nonalcoholic fatty liver disease: a meta-analysis of 3,355 individuals.Hepatobiliary Surg Nutr2023;12:658-70 PMCID:PMC10598314

[80] Lassailly G,Ntandja-Wandji LC.Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis.Gastroenterology2020;159:1290-301.e5

[81] Pais R,Bedossa P.Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.Hepatology2022;76:456-68

[82] Verrastro O,Castagneto-Gissey L.Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.Lancet2023;401:1786-97

[83] Mosko JD.Increased perioperative mortality following bariatric surgery among patients with cirrhosis.Clin Gastroenterol Hepatol2011;9:897-901

[84] Shimizu H,Maia M.Bariatric surgery in patients with liver cirrhosis.Surg Obes Relat Dis2013;9:1-6

[85] Diwan TS,Heimbach JK.Liver transplantation and bariatric surgery: timing and outcomes.Liver Transpl2018;24:1280-7

[86] Safwan M,Abouljoud MS.Outcome of liver transplantation in patients with prior bariatric surgery.Liver Transpl2017;23:1415-21

[87] Idriss R,Wu T.Impact of prior bariatric surgery on perioperative liver transplant outcomes.Liver Transpl2019;25:217-27

[88] Rogers CC,Alexander JW,Trofe J.Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.Clin Transplant2008;22:281-91 PMCID:PMC3660730

[89] Widmer J,Abbassi F.How best to combine liver transplantation and bariatric surgery?.Liver Int2024;44:566-76

[90] Campsen J,Shoen J.Adjustable gastric banding in a morbidly obese patient during liver transplantation.Obes Surg2008;18:1625-7

[91] Tariciotti L,Manzia TM.Combined liver transplantation and sleeve gastrectomy for end-stage liver disease in a bariatric patient: first European case-report.Int J Surg Case Rep2016;28:38-41 PMCID:PMC5037123

[92] Nesher E,Shlomai A.Simultaneous liver transplantation and sleeve gastrectomy: prohibitive combination or a necessity?.Obes Surg2017;27:1387-90

[93] Heimbach JK,Poterucha JJ.Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease.Am J Transplant2013;13:363-8

[94] Zamora-Valdes D,Kellogg TA.Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy.Hepatology2018;68:485-95

[95] Dayyeh BK, Bazerbachi F, Graupera I, Cardenas A. Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease.J Hepatol2019;71:1246-8

[96] Bustamante-Bernal MA,Zuckerman MJ.Endoscopic bariatric interventions in patients with chronic liver disease.Clin Liver Dis2022;26:139-48

[97] Singh S,Khan A,Ryan MB.Safety and efficacy of endoscopic sleeve gastroplasty worldwide for treatment of obesity: a systematic review and meta-analysis.Surg Obes Relat Dis2020;16:340-51 PMCID:PMC7009311

[98] Aoko O,Boland F,Ryan J.Meta-analysis: impact of intragastric balloon therapy on NAFLD-related parameters in patients with obesity.Aliment Pharmacol Ther2024;59:8-22

[99] Espinet Coll E,Díaz Galán P.Bariatric and metabolic endoscopy in the handling of fatty liver disease. A new emerging approach?.Rev Esp Enferm Dig2019;111:283-93

[100] Jagtap N,Katakwar A.Endoscopic sleeve gastroplasty - minimally invasive treatment for non-alcoholic fatty liver disease and obesity.Indian J Gastroenterol2021;40:572-9

[101] Hajifathalian K,Ang B.Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty.Gastrointest Endosc2021;93:1110-8

[102] Bazerbachi F,Rizk M.Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2021;19:146-54.e4 PMCID:PMC8106130

[103] Li AA,Ahmed A.Association of Sarcopenia and NAFLD: an overview.Clin Liver Dis2020;16:73-6 PMCID:PMC7474147

[104] Zhao Q,Deng Y.Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study.Nutr Diabetes2023;13:21 PMCID:PMC10651884

[105] Tarantino G,Citro V,Balsano C.Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?.Intern Emerg Med2023;18:1887-95 PMCID:PMC10543607

[106] Tagliafico AS,Torri L.Sarcopenia: how to measure, when and why.Radiol Med2022;127:228-37 PMCID:PMC8960583

[107] Bhanji RA,Moynagh MR.Differing impact of Sarcopenia and frailty in nonalcoholic steatohepatitis and alcoholic liver disease.Liver Transpl2019;25:14-24 PMCID:PMC7187989

[108] Lai JC,Terrault NA,Hayssen H.Frailty predicts waitlist mortality in liver transplant candidates.Am J Transplant2014;14:1870-9 PMCID:PMC4107151

[109] Xu CQ,Kappus MR.The relationship between frailty and cirrhosis etiology: from the functional assessment in liver transplantation (FrAILT) study.Liver Int2021;41:2467-73 PMCID:PMC8522207

[110] Charlton MR,Pedersen RA,Heimbach JK.Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.Gastroenterology2011;141:1249-53

[111] Haldar D, Kern B, Hodson J, et al; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. J Hepatol. 2019;71:313-22.

[112] Wong RJ,Ahmed A.Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.Hepatology2014;59:2188-95

[113] Yong JN,Ng CH.Outcomes of nonalcoholic steatohepatitis after liver transplantation: an updated meta-analysis and systematic review.Clin Gastroenterol Hepatol2023;21:45-54.e6

[114] Minich A,Shaikh NS.Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: a systematic review and meta-analysis.EClinicalMedicine2022;50:101534 PMCID:PMC9257342

[115] Diaz-Nieto R,Davidson BR.Recipient body mass index and infectious complications following liver transplantation.HPB2019;21:1032-8

[116] Giorgakis E,Bonaccorsi-Riani E.The effect of recipient body mass index and its extremes on survival and graft vascular and biliary complications after liver transplantation: a single center retrospective study.Ann Transplant2017;22:611-21

[117] Goldaracena N,Kim DS,Halazun KJ.Expanding the donor pool for liver transplantation with marginal donors.Int J Surg2020;82S:30-5

[118] Lim WH,Tan D.Natural history of NASH cirrhosis in liver transplant waitlist registrants.J Hepatol2023;79:1015-24

[119] O'Leary JG,Jennings L,Davis GL.Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants.Clin Gastroenterol Hepatol2011;9:700-4.e1 PMCID:PMC4408909

[120] Wong RJ,Cheung R.Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.Gastroenterology2015;148:547-55

[121] Kim WR,Heimbach JK.MELD 3.0: the model for end-stage liver disease updated for the modern era.Gastroenterology2021;161:1887-95.e4 PMCID:PMC8608337

[122] Linares I,Selzner N.Steatosis in liver transplantation: current limitations and future strategies.Transplantation2019;103:78-90

[123] Andert A,Schöning W.Grade of donor liver microvesicular steatosis does not affect the postoperative outcome after liver transplantation.Hepatobiliary Pancreat Dis Int2017;16:617-23

[124] Spitzer AL,Dick AA.The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment.Liver Transpl2010;16:874-84

[125] Dutkowski P,Slankamenac K.The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score.Ann Surg2012;256:861-8

[126] Croome KP,Taner CB.The “Skinny” on assessment and utilization of steatotic liver grafts: a systematic review.Liver Transpl2019;25:488-99

[127] Jackson KR,Haugen CE.Temporal trends in utilization and outcomes of steatotic donor livers in the United States.Am J Transplant2020;20:855-63

[128] Kwong AJ,Lake J.Impact of donor liver macrovesicular steatosis on deceased donor yield and posttransplant outcome.Transplantation2023;107:405-9 PMCID:PMC9877102

[129] Lascaris B,Porte RJ.Normothermic liver machine perfusion as a dynamic platform for regenerative purposes: what does the future have in store for us?.J Hepatol2022;77:825-36

[130] Patrono D,Gambella A.Viability assessment and transplantation of fatty liver grafts using end-ischemic normothermic machine perfusion.Liver Transpl2023;29:508-20 PMCID:PMC10106107

[131] Goldaracena N.Living donor liver transplantation.Curr Opin Organ Transplant2019;24:131-7

[132] Cotter TG,Wang J.Living donor liver transplantation in the United States: evolution of frequency, outcomes, center volumes, and factors associated with outcomes.Liver Transpl2021;27:1019-31 PMCID:PMC9257956

[133] Bhangui P,Choudhary N.Safe use of right lobe live donor livers with up to 20% macrovesicular steatosis without compromising donor safety and recipient outcome.Transplantation2020;104:308-16

[134] Neil DAH,Smith ML,Brunt EM.Banff consensus recommendations for steatosis assessment in donor livers.Hepatology2022;75:1014-25 PMCID:PMC9299655

[135] Tien C,Kwon Y.Contemporary strategies to assess and manage liver donor steatosis: a review.Curr Opin Organ Transplant2021;26:474-81 PMCID:PMC8447219

[136] Tejedor-Tejada J,Muñoz RN.De-novo nonalcoholic fatty liver disease at 5-years after liver transplantation: prevalence and predictive factors.Eur J Gastroenterol Hepatol2021;33:399-406

[137] Silva AC,Machado MV.Hepatic steatosis after liver transplantation: a systematic review and meta-analysis.Liver Transpl2023;29:431-48

[138] Saeed N,Sharma P,Sonnenday CJ.Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis.Transplantation2019;103:e345-54

[139] Galvin Z,Chen E.Predictors of de novo nonalcoholic fatty liver disease after liver transplantation and associated fibrosis.Liver Transpl2019;25:56-67

[140] Kim H,Lee K.Effect of PNPLA3 I148M polymorphism on histologically proven non-alcoholic fatty liver disease in liver transplant recipients.Hepatol Res2018;48:E162-71

[141] Satapathy SK,Kovalic AJ.Clinical and genetic risk factors of recurrent nonalcoholic fatty liver disease after liver transplantation.Clin Transl Gastroenterol2021;12:e00302 PMCID:PMC7864756

[142] Taneja S,Duseja A.NASH after liver transplantation: impact of immunosuppression.J Clin Exp Hepatol2023;13:835-40 PMCID:PMC10483005

[143] Lucey MR,Ojo L.Long-term management of the successful adult liver transplant: 2012 practice guideline by the American association for the study of liver diseases and the american society of transplantation.Liver Transpl2013;19:3-26

[144] Mikolasevic I,Blazic F.Noninvasive markers of liver steatosis and fibrosis after liver transplantation - where do we stand?.World J Transplant2021;11:37-53 PMCID:PMC8009059

[145] Ng CH,Lim XC.A diagnostic test meta-analysis evaluating imaging-based and blood biomarker-based assessment tools for fibrosis after liver transplantation.Liver Transpl2022;28:659-69

[146] Pissaia A Jr,Bernard D,Calmus Y.APRI and FIB-4 scores are useful after liver transplantation independently of etiology.Transplant Proc2009;41:679-81

[147] Kabbany MN,Guirguis J.Accuracy of noninvasive fibrosis scores in predicting the presence of fibrosis in patients after liver transplantation.Exp Clin Transplant2018;16:562-7

[148] Bhat M,Rollet-Kurhajec KC.Serum fibrosis biomarkers predict death and graft loss in liver transplantation recipients.Liver Transpl2015;21:1383-94

[149] Germani G,Rubbia-Brandt L.Management of recurrent and de novo NAFLD/NASH after liver transplantation.Transplantation2019;103:57-67

[150] Kanwal F,Loomba R.Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American association for the study of liver diseases practice guidance on nonalcoholic fatty liver disease.Hepatology2024;79:1212-9

[151] Bhat M,Sebastiani G.Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: a meta-analysis.PLoS One2017;12:e0185192 PMCID:PMC5617176

[152] Siddiqui MS,Stromberg K.Diagnostic performance of vibration-controlled transient elastography in liver transplant recipients.Clin Gastroenterol Hepatol2021;19:367-74 PMCID:PMC7541402

[153] Deurdulian C,Tchelepi H.Assessment of fibrosis in liver transplant recipients: diagnostic performance of shear wave elastography (SWE) and correlation of SWE findings with biopsy results.AJR Am J Roentgenol2019;213:W264-71

[154] Singh S,Keaveny A.Diagnostic accuracy of magnetic resonance elastography in liver transplant recipients: a pooled analysis.Ann Hepatol2016;15:363-76 PMCID:PMC5032623

[155] Choudhury A,Desmukh A,Eslam M.Post-liver transplant metabolic syndrome.J Clin Exp Hepatol2024;14:101368 PMCID:PMC10960134

[156] Pisano G,Consonni D.High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation: Preliminary results.Dig Liver Dis2020;52:84-90

[157] Hüsing A,Schmidt HH.Lipids in liver transplant recipients.World J Gastroenterol2016;22:3315-24 PMCID:PMC4806189

[158] VanWagner LB,Montag S.Blood pressure control according to clinical practice guidelines is associated with decreased mortality and cardiovascular events among liver transplant recipients.Am J Transplant2020;20:797-807 PMCID:PMC7042060

[159] Argo CK,Caldwell SH.Statins in liver disease: a molehill, an iceberg, or neither?.Hepatology2008;48:662-9

[160] Jenssen T.Post-transplant diabetes mellitus in patients with solid organ transplants.Nat Rev Endocrinol2019;15:172-88

[161] Hecking M,Döller D.Early basal insulin therapy decreases new-onset diabetes after renal transplantation.J Am Soc Nephrol2012;23:739-49 PMCID:PMC3312499

[162] Schwaiger E,Kurnikowski A.Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation: a multicenter randomized trial.J Am Soc Nephrol2021;32:2083-98 PMCID:PMC8455276

[163] Pena JM, Cusi K. Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia.J Clin Endocrinol Metab2023;109:e1-11

[164] Kristensen SL,Jhund PS.Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet Diabetes Endocrinol2019;7:776-85

[165] Kukla A,Merzkani M.The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients.Transplant Direct2020;6:e524 PMCID:PMC7004635

[166] Singh P,Washburn K,Meng S.Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients.Diabetes Obes Metab2019;21:1061-5

[167] Thangavelu T,Shivaswamy V.A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation.Diabetes Ther2020;11:987-94 PMCID:PMC7136376

[168] Tsamalaidze L,Arasi LC.Laparoscopic sleeve gastrectomy for morbid obesity in patients after orthotopic liver transplant: a matched case-control study.Obes Surg2018;28:444-50

[169] Morris MC,Kim Y.Delayed sleeve gastrectomy following liver transplantation: a 5-year experience.Liver Transpl2019;25:1673-81

[170] Barros F, Cardoso Faleiro Uba PH. Liver transplantation and bariatric surgery: a new surgical reality: a systematic review of the best time for bariatric surgery.Updates Surg2021;73:1615-22